Compare Inovio Pharmaceuticals Inc (INO) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Sprott Uranium Miners ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Sprott Uranium Miners ETF trades at $49.4. The key difference: Sprott Uranium Miners ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | URNM | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $2.87 | $83.99 |
52-Week Low | $1.05 | $44.14 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
URNM trades at $48.25, up 0.06% on the day, with technical indicators showing a bearish trend from moving averages but neutral oscillators. The ETF focuses on uranium miners, benefiting from rising nuclear energy demand driven by AI power needs. Recent news highlights strong performance, with URNM up 26% year-to-date as of April 2026, though some articles question miner valuations versus uranium prices.
The outlook for URNM is supported by long-term nuclear energy growth, but risks include volatility in uranium prices and concentrated miner exposure. Analyst sentiment is mixed, with some seeing upside from AI-driven power demand, while others caution on supply chain gaps and equity optimism diverging from fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
